A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

scientific article published on January 1991

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199101173240303
P698PubMed publication ID1984192

P2093author name stringCanadian Hydroxychloroquine Study Group
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectsystemic lupus erythematosusQ1485
hydroxychloroquineQ421094
P304page(s)150-154
P577publication date1991-01-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleA randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
P478volume324

Reverse relations

cites work (P2860)
Q371312832013 update: Hopkins lupus cohort
Q89234856A complicated multisystem flare of systemic lupus erythematosus during pregnancy
Q33777430A conceptual framework for clinical trials in SLE and other multisystem diseases
Q41926759A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus
Q41926859A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group
Q92737146An audit of the use of hydroxychloroquine in rheumatology clinics
Q47625953An overview of the treatment of childhood SLE.
Q34226976Antimalarial therapy: a panacea for mild lupus?
Q33529416Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.
Q34604474Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Q34297582Antimalarials--the 'real' advance in lupus
Q34129797Antimalarials.
Q93208741Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis
Q41916954Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus
Q36573884Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort
Q91973791Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients
Q30645037Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
Q51031046Biochemical characterization of ADP-ribose polymer metabolism in SLE.
Q64236851CD72 is a Negative Regulator of B Cell Responses to Nuclear Lupus Self-antigens and Development of Systemic Lupus Erythematosus
Q104559093COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
Q97526732Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine
Q49349531Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience
Q58603726Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study
Q90939644Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial
Q41913969Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry.
Q41943173Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Q41945144Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
Q41943280Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus
Q29615065Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Q35686749Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma
Q47133837Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey.
Q26741266Current and emerging treatment options in the management of lupus
Q41064137Cutaneous purpura of Sjögren syndrome successfully treated with hydroxychloroquine
Q24243533Dehydroepiandrosterone for systemic lupus erythematosus
Q24245412Dehydroepiandrosterone for systemic lupus erythematosus
Q33422958Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus
Q38776952Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood
Q37453947Developments in the clinical understanding of lupus
Q39449781Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus
Q46490126Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL).
Q36171764Disease activity assessment in SLE: do we have the right instruments?
Q45107051Disease specific problems related to drug therapy in pregnancy
Q36677040Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases
Q49835073Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus
Q41919066Early hydroxychloroquine macular toxicity
Q43417859Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.
Q31107094Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
Q50222848Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort
Q41913718Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial
Q36922219Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment
Q36634248Emerging drug therapies for systemic lupus erythematosus
Q33957431Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology
Q41917690Evidence of transplacental passage of hydroxychloroquine in humans
Q41922310Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study
Q92026856Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues
Q36793954Experimental designs for small randomised clinical trials: an algorithm for choice
Q41914711Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus
Q33731760Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.
Q41919391Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Q90157934Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy
Q36240425Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Q41915986Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Q41930905Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study
Q36906782Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
Q49383523Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience
Q38658480Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety
Q95302006Hydroxychloroquine hitting the headlines-retinal considerations
Q97646016Hydroxychloroquine in Dermatology and Beyond: Recent Update
Q38029146Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Q41927831Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Q41336601Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling
Q33411608Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies
Q36246166Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
Q99726452Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
Q55507790Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Q58608203Hydroxychloroquine retinopathy - implications of research advances for rheumatology care
Q96431036Hydroxychloroquine shortage
Q41942520Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
Q41944990Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis
Q53798136Hydroxychloroquine-Induced Erythema Multiforme.
Q26782822Hydroxychloroquine-related retinal toxicity
Q41934841Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome
Q46643929Hydroxychloroquine: the cornerstone of lupus therapy
Q47396929Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?
Q38883883Immunomodulators in SLE: Clinical evidence and immunologic actions
Q54365434Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.
Q64227620Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis
Q41917416Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study
Q50493859Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.
Q47743642Innate immune response gene expression profiles characterize primary antiphospholipid syndrome.
Q33744320Interferon-alpha: a therapeutic target in systemic lupus erythematosus
Q36302245Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Q61831377Le lupus érythémateux disséminé de l'enfant
Q99571380Leveraging Existing Strategies of Medication Stewardship to Preserve and Appropriately Use Critical Supplies
Q34227000Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations
Q39789199Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis
Q39608521Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome
Q36820979Lupus activity in pregnancy
Q36373318Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort
Q38608138Lupus nephritis: an update
Q40613454Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study.
Q40599033Lupus therapy
Q37121353Lupus: improving long-term prognosis
Q40086624Lymphadenitis and systemic lupus erythematosus
Q64084551Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing
Q77091376Management of collagen vascular diseases in childhood
Q44913899Managing lupus nephritis in pregnant women: comment on the article by Hahn et al.
Q36386474Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus
Q33777440Methodological issues of corticosteroid use in SLE clinical trials
Q53920423Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.
Q46076332Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study
Q89285609Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article
Q38816742New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity
Q34007922New concepts in antimalarial use and mode of action in dermatology
Q38026787New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.
Q90412368New therapeutic strategies in systemic lupus erythematosus management
Q38425824Optimizing the use of existing therapies in lupus.
Q28660110Pediatric lupus nephritis: Management update
Q40681350Pediatric rheumatic diseases.
Q41444884Periodontal implications: mucocutaneous disorders
Q36942997Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS.
Q38771936Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus
Q33555419Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort
Q33913777Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea
Q38600390Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.
Q47100353Predictors of incident proteinuria among patients with SLE.
Q37100267Pregnancy and autoimmune connective tissue diseases
Q34417671Pregnancy and lupus nephritis
Q77798505Pregnancy in SLE
Q38794847Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
Q41941085Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival
Q48341665Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Q52316454Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.
Q41917167Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort
Q33455990Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort
Q33945242Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States
Q41915954Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE
Q35824537Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?
Q52889113Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis.
Q74554250Reactions and interactions of some commonly used systemic drugs in dermatology
Q41582396Recognition and management of systemic lupus erythematosus
Q38826018Remission and withdrawal of therapy in lupus nephritis.
Q37768733Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect
Q35877606Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis
Q51031044Respiratory function in systemic lupus erythematosus: relation with activity and severity.
Q41931972Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
Q35222834Review: Treatment of Cutaneous Lupus Erythematosus
Q38295046Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus
Q98383294Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials
Q41915008Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group
Q47253208Sample size considerations for superiority trials in systemic lupus erythematosus (SLE).
Q36307429Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
Q31129756Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).
Q36074980Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy
Q38634472Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus
Q41946634Synthetic antimalarials
Q79878050Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview
Q73730202Systemic lupus erythematosus
Q84420574Systemic lupus erythematosus
Q39053129Systemic lupus erythematosus diagnosis and management
Q41933225Systemic lupus erythematosus flare-up manifesting as a cilioretinal artery occlusion
Q41944292Systemic lupus erythematosus in children and adolescents
Q34034374Systemic lupus erythematosus in the elderly.
Q83623481Systemic lupus erythematosus in the elderly: antimalarials in disease remission
Q53194239Systemic lupus erythematosus risk factors for coronary artery calcifications.
Q40506580Systemic lupus erythematosus--disease management
Q41920469Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients
Q41333508Systemic lupus erythematosus. Diagnosis and treatment
Q35597979Systemic lupus erythematosus. How to manage, when to refer
Q93193261Systemic lupus erythematosus: Diagnosis and clinical management
Q36792304Systemic lupus erythematosus: current state of diagnosis and treatment
Q38709337TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells
Q40951725The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?
Q41921799The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients
Q37634514The case for Zostavax vaccination in systemic lupus erythematosus
Q38540167The evolution of drug discovery in systemic lupus erythematosus
Q36577380The management of pediatric systemic lupus erythematosus
Q40188124The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit
Q38446538The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus
Q48867556The randomized placebo-phase design for clinical trials
Q37947108The role of antimalarial agents in the treatment of SLE and lupus nephritis
Q38897055Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus
Q34074960Therapy of systemic lupus erythematosus: new agents and new evidence
Q36147794Thrombosis in systemic lupus erythematosus: a review article
Q90048328Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity
Q34932177Toll-like receptors as potential therapeutic targets for multiple diseases
Q50726116Treatment Algorithms for Patients with Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al.
Q41207949Treatment Algorithms in Systemic Lupus Erythematosus
Q28087628Treatment of Bullous Systemic Lupus Erythematosus
Q41925126Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?
Q78814998Treatment of lupus nephritis
Q35456519Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies
Q38271125Treatment of severe lupus nephritis: the new horizon.
Q74022703Treatment of systemic lupus erythematosus
Q37974990Treatment of systemic lupus erythematosus: new advances in targeted therapy
Q36840264Treatment of systemic lupus erythematosus: which options do we have for therapy regimens?
Q33342024Treatment options for juvenile-onset systemic lupus erythematosus
Q43962381Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus
Q38764104What Causes Lupus Flares?
Q38920435Why targeted therapies are necessary for systemic lupus erythematosus
Q33410001Women, kidney disease, and pregnancy
Q84600129[Antimalarials: an update in rheumatic diseases]
Q78679215[Current therapy of lupus nephritis]
Q78506325[Kidney, lupus and pregnancy]
Q77114590[Lupus nephropathy: implications of a long course]
Q81057481[Systemic lupus erythematosus and accelerated atheromatosis]
Q89894663[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]

Search more.